Neuroscience
From today's Boston Globe:
Biogen Idec's top lawyer quits amid investigation
By Jeffrey Krasner
The Boston Globe
March 10, 2005
Thomas J. Bucknum, Biogen Idec's longtime top lawyer, resigned suddenly yesterday amid an inquiry by the Securities and Exchange Commission into sales of company stock by insiders around the time the company learned that patients taking its multiple sclerosis drug Tysabri had contracted a rare infection.
Bucknum sold 89,700 shares of Biogen Idec stock on Feb. 18, the day company executives learned that two patients in a long-term trial of Tysabri had the rare disease known as PML. According to documents the company filed with the SEC, Bucknum netted about $1.9 million from the sales.
[ ... Read the full article ... ]~
Note: "PML" stands for "progressive multifocal leukoencephalopathy."
- Business World: Biogen Idec, Protein Design Labs, & Daclizumab
From The Boston Globe:Biogen cuts deal to refill drug lineup Biotech to pay Calif. firm for rights to help develop MS treatment, 2 others By Jeffrey Krasner, Globe Staff The Boston Globe August 3, 2005 Making good on a promise to use a war chest of...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab)
From today's Boston Globe:Biogen MS drug gets lift from reports Medical journal suggests Tysabri may make a return By Jeffrey Krasner The Boston Globe 10 June 2005 Biogen Idec Inc.'s drug Tysabri might be safely given to multiple sclerosis patients...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) (cont.)
Additional information in follow-up to this morning's Boston Globe report, from Bloomberg:Elan, Biogen Decline on Report of New Tysabri Illness June 2 (Bloomberg) -- Shares of Elan Corp. and Biogen Idec Inc. tumbled after a fourth possible case of...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab)
From today's Boston Globe:A fourth death may be tied to Biogen's MS drug Finding could be blow to marketplace hopes By Jeffrey Krasner, Boston Globe Staff June 2, 2005 Biogen Idec Inc. has told the Food and Drug Administration that a fourth...
- Tysabri (natalizumab): Another Case Of Pml
A third case of progressive multifocal leukoencephalopathy (PML), as reported via The New York Times website: M.S. Drug Tied to a Death Published: March 31, 2005 By Bloomberg News Biogen Idec and the Elan Corporation said that a third patient had developed...
Neuroscience
Business World: Tysabri (Natalizumab) and Biogen Idec
From today's Boston Globe:
Biogen Idec's top lawyer quits amid investigation
By Jeffrey Krasner
The Boston Globe
March 10, 2005
Thomas J. Bucknum, Biogen Idec's longtime top lawyer, resigned suddenly yesterday amid an inquiry by the Securities and Exchange Commission into sales of company stock by insiders around the time the company learned that patients taking its multiple sclerosis drug Tysabri had contracted a rare infection.
Bucknum sold 89,700 shares of Biogen Idec stock on Feb. 18, the day company executives learned that two patients in a long-term trial of Tysabri had the rare disease known as PML. According to documents the company filed with the SEC, Bucknum netted about $1.9 million from the sales.
[ ... Read the full article ... ]
Note: "PML" stands for "progressive multifocal leukoencephalopathy."
- Business World: Biogen Idec, Protein Design Labs, & Daclizumab
From The Boston Globe:Biogen cuts deal to refill drug lineup Biotech to pay Calif. firm for rights to help develop MS treatment, 2 others By Jeffrey Krasner, Globe Staff The Boston Globe August 3, 2005 Making good on a promise to use a war chest of...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab)
From today's Boston Globe:Biogen MS drug gets lift from reports Medical journal suggests Tysabri may make a return By Jeffrey Krasner The Boston Globe 10 June 2005 Biogen Idec Inc.'s drug Tysabri might be safely given to multiple sclerosis patients...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) (cont.)
Additional information in follow-up to this morning's Boston Globe report, from Bloomberg:Elan, Biogen Decline on Report of New Tysabri Illness June 2 (Bloomberg) -- Shares of Elan Corp. and Biogen Idec Inc. tumbled after a fourth possible case of...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab)
From today's Boston Globe:A fourth death may be tied to Biogen's MS drug Finding could be blow to marketplace hopes By Jeffrey Krasner, Boston Globe Staff June 2, 2005 Biogen Idec Inc. has told the Food and Drug Administration that a fourth...
- Tysabri (natalizumab): Another Case Of Pml
A third case of progressive multifocal leukoencephalopathy (PML), as reported via The New York Times website: M.S. Drug Tied to a Death Published: March 31, 2005 By Bloomberg News Biogen Idec and the Elan Corporation said that a third patient had developed...